The Navigator - Navigenics Blog

Genetic insights into health and wellness

All posts from April, 2010

April 28, 2010

New from Navigenics—genetic insights to help you understand which medications work best for you

Posted 05:36 PM PDT

imagePerhaps your doctor thinks you should join the millions of people who’ve taken Plavix, a prescription medicine that helps prevent blood clots. But will it be effective for you? Or will another medication you are considering cause serious side effects? Starting a new medication can be a bit of a guessing game, with problems discovered only after the fact.

But your genetic makeup has a lot to say about how you respond to certain medications.

Now, a new type of genetic result from Navigenics can help you take even stronger strides towards a healthier future, by helping you understand which medications work best for you.

Your genetic code holds important information on how you respond to particular medications, and our new results help reveal it. The new Medications feature of the Navigenics service analyzes your genetic responses to 12 prescription drugs. These include everything from common medications, such as drugs designed to lower cholesterol or prevent blood clots, to more specialized drugs used to treat cancer or epilepsy. (See our complete list of medications.)

Read More

Categories:

| Email Post | Comments (0) | Permalink

April 28, 2010

Looking for new answers on Plavix and personal genetics

Posted 04:43 PM PDT

imagePlavix®, a prescription drug that helps prevent and treat blood clots, is one of the world’s top-selling medications. According to its manufacturer, doctors have prescribed it to more than 100 million people.Yet, genetics shows, popularity doesn’t always mean that a drug works for everyone.

And when it comes to Plavix®, that fact has some scientists working to see how genetic testing can provide better answers for people who take this medication.

Some people, because of their genetic makeup, don’t process Plavix® as effectively as others, leaving them vulnerable to dangerous blood clotting problems. In March, the U.S. Food and Drug Administration revised the drug label on Plavix® (also known by its generic name clopidogrel), emphasizing that people who carry certain genetic variants may not benefit fully from the drug. The FDA announcement also stressed that testing is available for a gene linked to a reduced response to Plavix®.

Since the vast majority of people who’ve taken Plavix® have never undergone genetic testing, researchers are now analyzing the ways that genetic insights can help.

Read More

Categories: Medication responses we analyze, Clopidogrel (Plavix) effectiveness

| Email Post | Comments (0) | Permalink